Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 26, 2023

SELL
$68.48 - $81.09 $4,793 - $5,676
-70 Reduced 2.31%
2,964 $0
Q3 2022

Oct 14, 2022

BUY
$0.13 - $76.84 $37 - $22,053
287 Added 10.45%
3,034 $215,000
Q2 2022

Jul 13, 2022

BUY
$72.62 - $79.98 $199,487 - $219,705
2,747 New
2,747 $211,000
Q1 2022

Apr 28, 2022

SELL
$61.48 - $73.72 $345,947 - $414,822
-5,627 Closed
0 $0
Q4 2021

Jan 14, 2022

BUY
$53.63 - $62.52 $1,930 - $2,250
36 Added 0.64%
5,627 $350,000
Q3 2021

Oct 22, 2021

BUY
$59.17 - $69.31 $1,834 - $2,148
31 Added 0.56%
5,591 $330,000
Q2 2021

Jul 21, 2021

BUY
$61.91 - $67.42 $1,981 - $2,157
32 Added 0.58%
5,560 $371,000
Q1 2021

Apr 28, 2021

SELL
$59.34 - $66.74 $423,094 - $475,856
-7,130 Reduced 56.33%
5,528 $348,000
Q4 2020

Jan 13, 2021

BUY
$57.74 - $65.43 $3,637 - $4,122
63 Added 0.5%
12,658 $791,000
Q3 2020

Oct 16, 2020

BUY
$57.43 - $63.64 $413,208 - $457,889
7,195 Added 133.24%
12,595 $5,000
Q2 2020

Jul 07, 2020

SELL
$54.82 - $64.09 $379,464 - $443,630
-6,922 Reduced 56.18%
5,400 $317,000
Q1 2020

Apr 27, 2020

BUY
$46.4 - $67.43 $1,345 - $1,955
29 Added 0.24%
12,322 $686,000
Q4 2019

Jan 09, 2020

BUY
$49.21 - $64.19 $136,606 - $178,191
2,776 Added 29.17%
12,293 $789,000
Q3 2019

Oct 15, 2019

BUY
$42.77 - $50.71 $5,303 - $6,288
124 Added 1.32%
9,517 $482,000
Q2 2019

Jul 30, 2019

BUY
$44.62 - $49.34 $419,115 - $463,450
9,393 New
9,393 $426,000
Q1 2019

Apr 30, 2019

SELL
$45.12 - $53.8 $420,789 - $501,738
-9,326 Closed
0 $0
Q4 2018

Feb 06, 2019

BUY
$48.76 - $63.23 $454,735 - $589,682
9,326 New
9,326 $484,000
Q1 2018

Apr 16, 2018

SELL
$59.92 - $68.98 $138,295 - $159,205
-2,308 Closed
0 $0
Q4 2017

Feb 12, 2018

BUY
$59.94 - $65.35 $138,341 - $150,827
2,308
2,308 $144,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Santori & Peters, Inc. Portfolio

Follow Santori & Peters, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Santori & Peters, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Santori & Peters, Inc. with notifications on news.